1
|
Shoji T, Muto R, Sakai R, Matsumura H, Uchida T, Kitta F, Inoue O, Kawata K, Akazawa M. Estimated medical costs of methicillin-resistant Staphylococcus aureus infection classified by polymerase chain reaction-based open reading frame typing in Japan. AIMS Microbiol 2022; 8:528-543. [PMID: 36694583 PMCID: PMC9834076 DOI: 10.3934/microbiol.2022034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2022] [Revised: 11/25/2022] [Accepted: 12/08/2022] [Indexed: 12/29/2022] Open
Abstract
This retrospective, observational cohort study investigated the economic impact of genotype by classifying methicillin-resistant Staphylococcus aureus (MRSA) by using the polymerase chain reaction-based open reading frame typing (POT) method. Using administrative claims and bacteriological data for April 2016 to March 2021 from the University of Yamanashi Hospital, we ascertained the POT1 numbers and classified MRSA as either "hospital-derived" or "community-derived". We defined MRSA-associated medical practices and estimated the associated medical costs. After applying inverse probability of treatment weighting (IPTW)-based adjustment for patient characteristics between the two groups, we estimated the differences in medical costs during the "total therapy period" (defined as the interval from specimen submission to Day 42 after the susceptibility report) and the "definitive therapy period" (defined as the interval from susceptibility reporting to Day 42). Among the 135 MRSA-infected patients, 54 and 81 were classified as having hospital-derived and community-derived MRSA infections, respectively. Significant differences in patient characteristics were observed with regard to age (p = 0.0478), sex (p = 0.0422), surgery (p = 0.0349), chemotherapy (p = 0.0457) and immunosuppressive drug use (p = 0.0222). The median duration of the definitive therapy was 29 and 27 days, and the mortality rate during this period was 11% and 5% for the hospital-derived and community-derived types, respectively. After IPTW-based adjustment, the medical costs for the total therapy period were 324,480 and 296,462 Japanese yen (JPY) per patient for the hospital-derived and community-derived types, respectively, whereas the medical costs for the definitive therapy period were 279,635 and 256,542 JPY per patient for the hospital-derived and community-derived types, respectively. No statistically significant difference was detected (p = 0.5813 and p = 0.6355, respectively). In this study, MRSA healthcare costs were compared according to the POT scores, and no statistically significant differences were observed between hospital-derived and community-derived MRSA infections.
Collapse
Affiliation(s)
- Tomokazu Shoji
- Department of Pharmacy, University of Yamanashi Hospital, 1110, Shimokato, Chuo, Yamanashi 409–3898, Japan,Department of Public Health and Epidemiology, Meiji Pharmaceutical University, 2–522–1, Noshio, Kiyose, Tokyo 204–8588, Japan,Division of Infection Control and Prevention, University of Yamanashi Hospital, 1110, Shimokato, Chuo, Yamanashi 409–3898, Japan,* Correspondence: ; Tel: +81552731111; Fax: +81552736672
| | - Ryusei Muto
- Department of Public Health and Epidemiology, Meiji Pharmaceutical University, 2–522–1, Noshio, Kiyose, Tokyo 204–8588, Japan
| | - Ryoko Sakai
- Department of Public Health and Epidemiology, Meiji Pharmaceutical University, 2–522–1, Noshio, Kiyose, Tokyo 204–8588, Japan
| | - Hiroki Matsumura
- Department of Pharmacy, University of Yamanashi Hospital, 1110, Shimokato, Chuo, Yamanashi 409–3898, Japan,Division of Infection Control and Prevention, University of Yamanashi Hospital, 1110, Shimokato, Chuo, Yamanashi 409–3898, Japan
| | - Takashi Uchida
- Division of Infection Control and Prevention, University of Yamanashi Hospital, 1110, Shimokato, Chuo, Yamanashi 409–3898, Japan,Department of Clinical Laboratory, University of Yamanashi Hospital, 1110, Shimokato, Chuo, Yamanashi 409–3898, Japan
| | - Fumihiko Kitta
- Department of Pharmacy, University of Yamanashi Hospital, 1110, Shimokato, Chuo, Yamanashi 409–3898, Japan
| | - Osamu Inoue
- Division of Infection Control and Prevention, University of Yamanashi Hospital, 1110, Shimokato, Chuo, Yamanashi 409–3898, Japan
| | - Keishi Kawata
- Department of Pharmacy, University of Yamanashi Hospital, 1110, Shimokato, Chuo, Yamanashi 409–3898, Japan
| | - Manabu Akazawa
- Department of Public Health and Epidemiology, Meiji Pharmaceutical University, 2–522–1, Noshio, Kiyose, Tokyo 204–8588, Japan
| |
Collapse
|
2
|
Differentiation of Community-Associated and Livestock-Associated Methicillin-Resistant Staphylococcus aureus Isolates and Identification of spa Types by Use of PCR and High-Resolution Melt Curve Analysis. J Clin Microbiol 2020; 58:JCM.02088-19. [PMID: 32132185 DOI: 10.1128/jcm.02088-19] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2019] [Accepted: 02/24/2020] [Indexed: 11/20/2022] Open
Abstract
Infections due to methicillin-resistant Staphylococcus aureus (MRSA) are present worldwide and represent a major public health concern. The capability of PCR followed by high-resolution melt (HRM) curve analysis for the detection of community-associated and livestock-associated MRSA strains and the identification of staphylococcal protein A (spa) locus was evaluated in 74 MRSA samples which were isolated from the environment, humans, and pigs on a single piggery. PCR-HRM curve analysis identified four spa types among MRSA samples and differentiated MRSA strains accordingly. A nonsubjective differentiation model was developed according to genetic confidence percentage values produced by tested samples, which did not require visual interpretation of HRM curve results. The test was carried out at different settings, and result data were reanalyzed and confirmed with DNA sequencing. PCR-HRM curve analysis proved to be a robust and reliable test for spa typing and can be used as a tool in epidemiological studies.
Collapse
|
3
|
Watanabe Y, Oikawa N, Hariu M, Seki M. Evaluation of agar culture plates to efficiently identify small colony variants of methicillin-resistant Staphylococcus aureus. Infect Drug Resist 2019; 12:1743-1748. [PMID: 31417291 PMCID: PMC6593740 DOI: 10.2147/idr.s207057] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2019] [Accepted: 05/22/2019] [Indexed: 11/23/2022] Open
Abstract
Background: Small-colony variants of methicillin-resistant Staphylococcus aureus (SCV-MRSA) recently were described as slow-growing, thymidine-dependent strains; typically, SCV-MRSA were isolated from patients receiving sulfamethoxazole-trimethoprim, but detection of these strains frequently was delayed because of their small colony size and slow growth. Bacteremia cases due to SCV-MRSA sometimes become lethal when the initiation of treatment with intravenous anti-methicillin-resistant Staphylococcus aureus (MRSA) drugs starts too late. Methods: Here, we evaluated the use of general MRSA-specific agar plates in Japan, including MS-CFX, X-MRSA, and CHROMagar, for the efficient detection of SCV-MRSA, including the comparative detection efficiencies of these media for stock strains and clinical isolates. Results: Among the three MRSA-specific agar plates that were tested, X-MRSA and CHROMagar showed similar detection efficiencies for both 24 and 48 hrs culturing; in contrast, MS-CFS did not permit the detection of SCV-MRSA in stock strains. For clinical isolates of SCV-MRSA, X-MRSA plates permitted detection of the smallest and slowest-growing colonies of SCV-MRSA at 48 hrs of culturing; in contrast, CHROMagar and MS-CFX sometimes did not identify SCV-MRSA at 24 and 48 hrs. Conclusion: Optimization of media and incubation times will be necessary for efficient identification for SCV-MRSA, which would prevent delays in diagnosis and treatment with anti-MRSA drugs.
Collapse
Affiliation(s)
- Yuji Watanabe
- Division of Infectious Diseases and Infection Control.,Laboratory for Clinical Microbiology, Tohoku Medical and Pharmaceutical University Hospital, Sendai City, Miyagi, Japan
| | - Nozomi Oikawa
- Division of Infectious Diseases and Infection Control.,Laboratory for Clinical Microbiology, Tohoku Medical and Pharmaceutical University Hospital, Sendai City, Miyagi, Japan
| | - Maya Hariu
- Division of Infectious Diseases and Infection Control.,Laboratory for Clinical Microbiology, Tohoku Medical and Pharmaceutical University Hospital, Sendai City, Miyagi, Japan
| | - Masafumi Seki
- Division of Infectious Diseases and Infection Control
| |
Collapse
|